CA-EAG-LABORATORIES
9.12.2020 14:02:15 CET | Business Wire | Press release
EAG Laboratories is pleased to announce the completed installation of a ThermoFisher Scientific Themis Z Transmission Electron Microscope (TEM) at our Silicon Valley facility. This next generation, ultra-high-resolution TEM is the first available in an independent laboratory in North America and is the second Themis Z owned by EAG Laboratories.
The Themis Z is a monochromated, probe-corrected TEM operated in an electron energy range of 30-300 kilovolts. Outside of its pure imaging capabilities, the microscope provides unprecedented access to physical and chemical properties for advanced materials research. With this technology, EAG scientists can provide our clients with:
- Sub-atomic spatial resolution
- State-of-the-art chemical analysis
- Revolutionary mapping capability for a wide variety of physical material properties
- Improved atomic resolution for compound semiconductors, atomic layer etching and advanced node devices
This leading edge TEM gives EAG Laboratories’ clients the highest resolution and deeper insights into the materials structure of their devices, which will increase their ability to improve device performance and reduce time to market. The Themis Z complements the company’s existing global microscopy services and strengthens its position as the world leader in advanced microscopy services.
EAG Laboratories is delighted to offer its clients data analysis along with the highest resolution images commercially available from a TEM. The company can now serve its clients in North America, Europe and Asia with these powerful advanced imaging capabilities coupled with its global scientific microscopy staff to solve both the routine and the most challenging materials analysis problems.
About EAG Laboratories
EAG Laboratories is the global leader in materials and engineering sciences and supports thousands of clients with 20+ locations throughout Europe, Asia, and the U.S. For more information visit eag.com. EAG Laboratories’ parent company, Eurofins Scientific, is a multi-billion global leader in scientific testing services with a portfolio of over 200,000 validated analytical methods.
About Eurofins – the global leader in bio-analysis
With over 50,000 staff across a network of more than 800 laboratories in over 50 countries , Eurofins’ companies offer a portfolio of over 200,000 analytical methods .
Eurofins Shares are listed on Euronext Paris Stock Exchange.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005022/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Completes Acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights Business, Expanding Digital Commerce Intelligence Capabilities1.7.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced that it has completed the acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights business. The acquired business operates in China under the YiMian (“一面”) brand and is a leading provider of eCommerce, social commerce, and digital shelf solutions. The acquisition expands NIQ’s capabilities across China and Southeast Asia and strengthens its ability to measure and understand consumer behavior across retail, eCommerce, social commerce, and digital environments — advancing NIQ’s mission to deliver The Full View™, the most complete understanding of consumer behavior across online and offline channels. It also enhances NIQ’s data and analytics foundation by expanding access to rich digital commerce signals that support the development of more advanced analytics and AI-powered solutions. By bringing together NIQ’s global intelligence, analytics, and retail measurement capabilities with the ac
Azalea Vision Awarded Prestigious EIC Accelerator Funding to Advance Smart Contact Lens into Clinical Development1.7.2026 13:00:00 CEST | Press release
Belgium’s only company selected in the latest EIC Accelerator funding round.Up to €7.5 million in blended finance: a €2.5 million non-dilutive grant plus a planned €5 million EIC Fund equity investment.Funding advances Azalea’s smart contact lens platform from technical validation into the clinic.Selection provides independent validation of Azalea Vision’s technology, clinical strategy and commercial potential. Azalea Vision, a Belgian healthtech company building the first medical-grade smart contact lens, today announced it has been selected for the European Innovation Council (EIC) Accelerator, the European Union’s flagship program for breakthrough, market-creating deep tech. Azalea is the only Belgian company selected in this round and will receive up to €7.5 million, including a non-dilutive €2.5 million grant and a planned €5 million equity investment from the EIC Fund, to advance its medical-grade smart contact lens platform into clinical development. This press release features
Croma-Pharma Announces FDA Approval of Obagi saypha® ChIQ™ in the United States1.7.2026 12:34:00 CEST | Press release
ChIQ™ becomes the second FDA-approved product from Croma's saypha® portfolio in the U.S., expanding treatment options for facial volume restoration. Wrapping up the first half of 2026 with another important milestone, Croma-Pharma announces the FDA approval of Obagi saypha® ChIQ™ in the United States. Obagi saypha® ChIQ™ injectable hyaluronic acid gel is approved for cheek augmentation and correction of midface contour deficiencies in adults over the age of 21. Developed and manufactured by Croma-Pharma and commercialized by Obagi Medical, a Waldencast company, in the U.S., ChIQ™ follows the approval of Obagi saypha® MagIQ™ in September 2025 and further broadens the availability of Croma's injectable aesthetic solutions in the United States. As demand for minimally invasive aesthetic treatments continues to grow, the approval broadens the range of treatment options available to healthcare professionals and patients seeking safe and natural-looking aesthetic outcomes. "With the approval
Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer to Accelerate Global Commercial Expansion1.7.2026 12:01:00 CEST | Press release
Rezon Bio, a science-driven European biologics contract development and manufacturing organization (CDMO), today announced the appointment of Dr. Hubert Scholze as Chief Business Officer (CBO), effective July 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701630118/en/ Dr. Hubert Scholze, Chief Business Officer, Rezon Bio As a member of Rezon Bio’s Executive Leadership Team, Dr. Hubert Scholze will lead the company’s commercial functions, overseeing Business Development, Market Intelligence, Global Marketing, Proposal Management and Project Management. Hubert Scholze, PhD will be responsible for Rezon Bio’s commercial strategy, strengthening strategic partnerships, supporting the company’s continued international growth, and ensuring a seamless client experience from initial engagement to program execution. His appointment comes at pivotal moment for Rezon Bio as the company continues to strengthen its integrated
CoStar Group Invests in Wikicasa, Italy’s Agent-Backed Real Estate Marketplace1.7.2026 12:00:00 CEST | Press release
Transaction will result in an approximately 30% stake in the company and support innovation and digital transformation in the Italian real estate market CoStar Group, Inc. (NASDAQ: CSGP), a global leader in online real estate marketplaces, information, analytics and 3D digital twin technology in the property markets, today announced an investment in Wikicasa, Italy’s agent-backed real estate marketplace. The transaction will result in CoStar Group acquiring an approximately 30% stake in Wikicasa. Wikicasa’s shareholder base includes Italy’s leading real estate agencies - including Tecnocasa Group, Gabetti Group, RE/MAX Italy, and Tempocasa. Wikicasa.it is an agent-driven platform that brings together leading real estate professionals across Italy to deliver a high-quality, data-rich marketplace of over 600,000 listings, more than 100,000 of which are commercial. It provides consumers with comprehensive property listings while equipping agents with modern data and intelligence tools to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom